3D InSight™ Tumor Relapse Assay Service

Assess tumor chemoresistance and recurrence potential in vitro in response to repeat or single-pulse drug dosing using advanced 3D tumor models

  • Assess your test compound in 3D InSight™ Tumor Microtissues (monoculture or co-culture)
  • Utilize kinetic size profiling (spheroid area) and viability (CellTiter-Glo®) endpoints to first determine baseline potency (EC20 and EC50) and efficacy (maximum response) values over 5 day exposure
  • Determine relapse classification comparing growth kinetics over 10 days following repeat vs. single-pulse dosing 
  • Receive potency (EC20 and EC50) and efficacy (maximum response) values, growth constants, and relapse classification value for your drug and 3 control compounds (Taxol, Doxorubicin, Staurosporine)

learn more button no background quote



  • For pricing information and shipping costs, please request a quote, indicating the desired product, amount, and the preferred shipment date.


    Catalog # Description

    3D InSight™ Tumor Relapse Assay Service (1 compound, 3 controls, 1 model)


    Please inquire for different numbers of compounds. Volume discounts for larger testing programs are available.


  • Classify the kinetics of tumor relapse potential in vitro

    Sequentially determine the response of a tumor to your drug, and then the kinetics of tumor re-growth (relapse) following removal of the drug. We use phenotypic (size-based) assessment of spheroid growth with the Cell3iMager, allowing continuous, non-lytic monitoring off spheroid growth over time.   

    • Determination of EC20 and EC50 values using ATP and size after 5 day exposure (test drug & TAX, DOX, STA)
    • Relapse assay comparing pulsed dosing (day 0 only) at EC50 and EC20 to repeat dosing (day 0, 3, 7) at max response concentration over 10 days
    • Relapse classification

    Chemoresistance Assay Services in 3D Tumor Microtissues

    Example tumor relapse kinetics for Doxorubicin showing recovery of HCT-116 tumor spheroid growth following single treatment (pulsed-green line) at the EC50 dose, compared to repeat-dosing over 10 days at the max response dose (gray line) or vehicle control (black line). Growth constants are used to determine relapse classification values at EC20 and EC50 values. 

    Model systems

    Exposure time

    • Potency and efficacy determination:  5 days. 1 dose at day 0
    • Relapse classification:  10 days (single dose at EC20 and EC50, repeat dose at maximum efficacy concentration at day 0, 3, and 7)


    • Biochemical: ATP-based dose-response curve for test compounds after 10 days using Promega CellTiter-Glo®
    • Phenotypic: Size-based dose-response curve of test compounds after 10 days, growth kinetics of selected concentrations over time using Cell3iMager 

    Test compound concentration

    • Potency and efficacy determination:  11-point dose-response curve, each data point in duplicate
    • Relapse classification: EC20, EC50, maximum efficacy concentration for test compound and controls

    Data delivery

    • ATP dose-response curve of test compounds (day 5)
    • Size-based dose-response curve of test drug and controls (day 5) and growth kinetics over time using the Cell3iMager
    • Potency (EC20 and EC50) values
    • Efficacy (max response)
    • Growth constants
    • Standard deviation of DMSO and vehicle control
    • Written report including materials and methods, compound information, graphs, and data summary table

    Compound requirements

    • 30 µl of 200x DMSO-stock

    Quality control

    • 0.5% DMSO, 3 control compounds (Taxol, Doxorubicin, Staurosporine)


Company video